Loading…
Invivyd, Inc. is projected to decline to $1.07 by 2027, a -5% move from its current price of $1.13. IVVD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.07 | $1.13 | $1.19 | -0.09% |
| May 30 | $1.04 | $1.13 | $1.22 | -0.18% |
| May 31 | $1.02 | $1.13 | $1.24 | -0.27% |
| Jun 1 | $1.01 | $1.13 | $1.26 | -0.36% |
| Jun 2 | $0.9946 | $1.12 | $1.27 | -0.45% |
| Jun 3 | $0.9821 | $1.12 | $1.29 | -0.54% |
| Jun 4 | $0.9707 | $1.12 | $1.30 | -0.63% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9707 | $1.12 | $1.30 | -0.63% |
| Week 2 | $0.9081 | $1.12 | $1.37 | -1.25% |
| Week 3 | $0.8616 | $1.11 | $1.43 | -1.87% |
| Week 4 | $0.8234 | $1.10 | $1.47 | -2.48% |
| Week 5 | $0.7906 | $1.10 | $1.52 | -3.09% |
| Week 6 | $0.7616 | $1.09 | $1.55 | -3.70% |
| Week 7 | $0.7355 | $1.08 | $1.59 | -4.30% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Invivyd, Inc. engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States.
The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc.
and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.
Invivyd, Inc. trades in the healthcare sector under the IVVD ticker. The current price is $1.10 and the market capitalization is $324.07M, with a rank of 3448.
The price outlook from the provided forecast shows modest near-term activity with volatility into the mid-decade, followed by stronger upside toward 2050. In 2026 the average price is forecast at $1.10 with a neutral stance; by 2040 the average is $1.46 with a bullish signal and by 2050 the average is $3.00 with a bullish signal and a max of $6.90.
A major floor 46.6% below — a decisive break under it would weaken the trend.
The nearest floor, 8.0% below — buyers have tended to step in here.
The nearest ceiling, 54.0% above — a clean break opens room to run.
A major ceiling 116.8% above — clearing it would confirm fresh momentum.
Key IVVD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IVVD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.11 | Buy | $1.12 | Buy |
| MA 10 | $1.15 | Sell | $1.17 | Sell |
| MA 20 | $1.30 | Sell | $1.27 | Sell |
| MA 50 | $1.42 | Sell | $1.43 | Sell |
| MA 100 | $1.67 | Sell | $1.56 | Sell |
| MA 200 | $1.68 | Sell | $1.56 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.69 | Neutral |
| Stoch RSI (14) | 35.15 | Neutral |
| CCI (20) | -69.62 | Neutral |
| Williams %R (14) | -80.85 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -24.67 | Sell |
| Bollinger %B (20,2) | 0.25 | Neutral |
| Stochastic %K (14) | 19.15 | Buy |
| TRIX (15) | -0.90 | Sell |
| Awesome (5,34) | -0.33 | Sell |
| Ultimate (7,14,28) | 33.25 | Neutral |
| Momentum (10) | -0.36 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 1.10 | Buy |
| ADX (14) | 19.77 | Neutral |
| ATR (14) | 0.06 | Info |
The 30-day technical picture shows bearish sentiment with RSI(14) at 40. The stock trades below the SMA50 of $1.45 and the SMA200 of $1.68, suggesting a soft near-term bias. Key support sits at $1.04 and resistance at $1.74, defining a limited trading corridor. The 30-day price range spans from $0.7496 to $1.61, highlighting the current volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.04 | $1.13 | $1.46 | 0% | Neutral | |
| $0.7691 | $1.07 | $1.61 | -5% | Neutral | |
| $0.6488 | $0.9568 | $1.53 | -15% | Bearish | |
| $0.5248 | $0.8147 | $1.37 | -28% | Bearish | |
| $0.5623 | $0.9147 | $1.59 | -19% | Bearish | |
| $0.6648 | $1.13 | $2.04 | 0% | Neutral | |
| $0.7404 | $1.31 | $2.44 | +16% | Neutral | |
| $0.6992 | $1.29 | $2.46 | +14% | Neutral | |
| $0.5625 | $1.08 | $2.11 | -4% | Neutral | |
| $0.5896 | $1.18 | $2.36 | +4% | Neutral | |
| $0.6771 | $1.50 | $3.31 | +33% | Bullish | |
| $1.38 | $3.06 | $7.04 | +171% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.04 | $1.13 | $1.35 | +0.00% |
| June 2026 | $0.9193 | $1.10 | $1.37 | -2.43% |
| July 2026 | $0.8537 | $1.04 | $1.33 | -5.56% |
| August 2026 | $0.8543 | $1.06 | $1.37 | +1.41% |
| September 2026 | $0.8473 | $1.06 | $1.40 | +0.29% |
| October 2026 | $0.7898 | $0.9972 | $1.33 | -5.84% |
| November 2026 | $0.7802 | $0.9941 | $1.35 | -0.31% |
| December 2026 | $0.8313 | $1.07 | $1.46 | +7.48% |
Click any year to see its month-by-month IVVD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, IVVD could reach as high as $1.46, with a base case around $1.13 and support toward $1.04 — roughly 0% from $1.13. Price action looks broadly range-bound.
Expect IVVD to range from $0.7691 to $1.61 through 2027. The $1.07 average target implies a -5% move from current prices. That is -5% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The IVVD price prediction for 2028 points to an average of $0.9568 (low $0.6488, high $1.53) — a potential decline of -15% on today's $1.13. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2029, IVVD is projected to trade between $0.5248 and $1.37, averaging $0.8147 — a potential decline of -28% from today's $1.13. That is -15% versus the projected 2028 average. Expect choppier, lower action through this leg of the cycle.
Invivyd, Inc.'s 2030 outlook centres on $0.9147, within a $0.5623 to $1.59 range. That is up +12% on the projected 2029 average. That marks a -19% change versus current levels. A cyclical pullback looks likely — prices rarely move in a straight line.
By 2031, IVVD could reach as high as $2.04, with a base case around $1.13 and support toward $0.6648 — roughly 0% from $1.13. A consolidation phase looks the most probable path here.
Expect IVVD to range from $0.7404 to $2.44 through 2032. The $1.31 average target implies a +16% move from current prices. That is up +16% on the projected 2031 average. Price action looks broadly range-bound.
The IVVD price prediction for 2033 points to an average of $1.29 (low $0.6992, high $2.46) — a potential gain of +14% on today's $1.13. A consolidation phase looks the most probable path here.
In 2034, IVVD is projected to trade between $0.5625 and $2.11, averaging $1.08 — a potential decline of -4% from today's $1.13. That is -16% versus the projected 2033 average. Price action looks broadly range-bound.
Invivyd, Inc.'s 2035 outlook centres on $1.18, within a $0.5896 to $2.36 range. That is up +9% on the projected 2034 average. That marks a +4% change versus current levels. A consolidation phase looks the most probable path here.
By 2040, IVVD could reach as high as $3.31, with a base case around $1.50 and support toward $0.6771 — roughly +33% from $1.13. Momentum favours further upside here.
Expect IVVD to range from $1.38 to $7.04 through 2050. The $3.06 average target implies a +171% move from current prices. That is up +103% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in IVVD today (≈ 884.955752 IVVD) could be worth
$2,706.91
+$1,706.91 (+171%) by 2050 · US Dollar
Based on the average projected IVVD price of $3.06 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IVVDwould be worth at today's price.
$1,000 invested in IVVD on May 27, 2025 (≈ 1,112.347066 IVVD) would be worth
$1,256.95
+$256.95 (+25.7%) today · 1.26× · US Dollar
Based on a IVVD entry price of $0.899 vs. today's $1.13.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.09 | $1,036.7 | +3.7% |
| 1 month ago | $1.46 | $773.97 | -22.6% |
| 3 months ago | $1.7 | $664.71 | -33.5% |
| 6 months ago | $2.43 | $465.02 | -53.5% |
| 1 year ago | $0.899 | $1,256.95 | +25.7% |
| All time (4.8y) ago | $20.88 | $54.12 | -94.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IVVD forecast.
Our base-case forecast reaches $2.30 around 2050.
Implied market cap at $2.30: $677.6M
The forecast project a shift from neutral and bearishly biased readings in the early years to stronger upside later in the period. The 2026 avg price is $1.10 with 0% ROI and neutral sentiment; 2027 avg $1.03 with -6.7% ROI; 2028 avg $0.93 with -15.4% ROI; 2029 avg $0.7869 with -28.5% ROI; 2030 avg $0.8756 with -20.4% ROI and bearish sentiment. The 2031 avg climbs to $1.11 with 0.9% ROI and neutral tone; 2032 avg $1.28 with 16% ROI and neutral; 2033 avg $1.24 with 12.7% ROI and neutral; 2034 avg $1.06 with -4% ROI and neutral; 2035 avg $1.14 with 3.7% ROI and neutral.
The forecast turns bullish by 2040 with avg $1.46, max $3.21 and 32.6% ROI; and by 2050 the average is $3.00, max $6.90 and 172.6% ROI, both with bullish sentiment.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $0.8756 with a min of $0.538 and a max of $1.53, for a -20.4% ROI and a bearish outlook.
Near-term forecasts show neutral to bearish readings in 2026–2030, with a 2026 avg of $1.10 and 0% ROI, followed by further declines before turning more positive in 2040–2050 (2040 avg $1.46, 32.6% ROI; 2050 avg $3.00, 172.6% ROI).
Yes—the 2050 forecast lists an avg of $3.00 with a max of $6.90 and a 172.6% ROI; the 2040 max is $3.21.
Current price is $1.10 and market cap is $324.07M.
RSI(14) is 40 with bearish sentiment; SMA50 is $1.45 and SMA200 is $1.68. Support is at $1.04 and resistance at $1.74, with a 30-day range of $0.7496 to $1.61.
Invivyd, Inc. Community Discussion
0Share your Invivyd, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.